Reprogramming Postablation Tumor Immune Microenvironment with Dual-Function Nanotherapeutic Immunomodulator for Synergistic Antitumor Immunity and Recurrence Suppression
ACS Nano · 2026
DOI: 10.1021/acsnano.5c10858 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Nano, 2026. Verfasst von Bing Wang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Ultrasound, Peking University Cancer Hospi…. Hauptthemen laut MEDLINE: Tumor Microenvironment, Immunologic Factors, Nanoparticles, Neoplasm Recurrence, Local. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: National Key Research and Development Program of China, Beijing Municipal Health Commission, Natural Science Foundation of Beijing Municipality.
Abstract (Originalsprache)
Radiofrequency ablation (RFA) has emerged as a predominant minimally invasive approach for liver tumors, achieving favorable therapeutic outcomes and triggering a systemic immune response via the release of tumor-associated antigens. However, postablation tumor recurrence remains a critical challenge in clinics. Our previous studies revealed that ablation-induced immunosuppression, primarily characterized by the expansion and activation of myeloid-derived suppressor cells (MDSCs), critically compromised the host's antitumor immunity, impeding residual tumor eradication and fostering a permissive niche for recurrence. To decisively address this fundamental limitation and harness the potential of ablation to stimulate antitumor immunity, we proposed a nanotherapeutic immunomodulatory strategy that synchronously reversed postablation MDSC-driven immunosuppression ("release the immunosuppressive brakes") while activating the stimulator of interferon gene (STING) pathway-mediated antitumor immune priming ("apply the immunostimulatory accelerator") in the systemic immune landscape. Through rational design, we engineered the nanotherapeutic immunomodulators (termed cA@NPs, where NPs are nanoparticles) coencapsulating the STING agonist 2',3'-cyclic guanosine adenosine monophosphate (cGAMP) and the MDSC-differentiating agent all-trans retinoic acid (ATRA), effectively overcoming their disparate pharmacokinetic profiles while ensuring spatiotemporally coordinated delivery. The residual tumor models provided definitive evidence that reversing postablation MDSC-driven immunosuppression was essential for achieving more effective antitumor immunity. Comprehensive preclinical evaluations further demonstrated the cA@NPs' robust capacity to suppress micrometastasis, distant tumors, and orthotopic lesions via multidimensional remodeling of the postablation immune landscape. These findings established a mechanistic foundation for the clinical translation of ablation-synergized nanotherapy, effectively bridging localized thermal intervention with systemic immune potentiation to address tumor recurrence.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Ultrasound, Peking University Cancer Hospital & Institute, Peking University, Beijing 100142, China.
- Beijing Key Laboratory of Molecular Pharmaceutics and Drug Delivery Systems, School of Pharmaceutical Sciences, Peking University, Beijing 100191,China.
- State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University, Beijing 100191, China.
- Peking University Hospital of Stomatology, Beijing 100081, China.
ORCID-Profile: Qiang Zhang, Hao Wu
Förderung
- National Key Research and Development Program of China
- Beijing Municipal Health Commission
- Natural Science Foundation of Beijing Municipality
- National Natural Science Foundation of China
- Natural Science Foundation of Shandong Province
- Peking University Cancer Hospital
Zitieren
APA
Wang, B., Yan, Z., Shen, Y., Fan, S., Wang, S., Wang, W., Zhang, Q., Yang, W., He, B., & Wu, H. (2026). Reprogramming Postablation Tumor Immune Microenvironment with Dual-Function Nanotherapeutic Immunomodulator for Synergistic Antitumor Immunity and Recurrence Suppression. ACS Nano. https://doi.org/10.1021/acsnano.5c10858
Vancouver
Wang B, Yan Z, Shen Y, Fan S, Wang S, Wang W, et al. Reprogramming Postablation Tumor Immune Microenvironment with Dual-Function Nanotherapeutic Immunomodulator for Synergistic Antitumor Immunity and Recurrence Suppression. ACS Nano. 2026. doi:10.1021/acsnano.5c10858
BibTeX
@article{Wang2026,
author = {Wang, Bing and Yan, Zhicheng and Shen, Yuhan and Fan, Shumin and Wang, Song and Wang, Wenbo and Zhang, Qiang and Yang, Wei and He, Bing and Wu, Hao},
title = {Reprogramming Postablation Tumor Immune Microenvironment with Dual-Function Nanotherapeutic Immunomodulator for Synergistic Antitumor Immunity and Recurrence Suppression},
journal = {ACS Nano},
year = {2026},
doi = {10.1021/acsnano.5c10858}
}
EUVIMED